文献速递前列腺癌

肥胖与非转移性去势抵抗性前列腺癌患者全因死亡率降低相关:SEARCH数据库结果

Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
PubMed 文献 · BJU Int · 2018-04-10

调整混杂因素后,肥胖与全因死亡率(ACM)降低显著相关(HR 0.79,P=0.016),但与前列腺癌特异性死亡率(PCSM)和转移均无显著关联。结论提示肥胖与非mCRPC患者总生存改善相关,但需更大研究确认。

要点

  • 在non-mCRPC患者中,肥胖(BMI≥30 kg/m2)与全因死亡率降低独立相关(HR 0.79,P=0.016)。
  • 肥胖与前列腺癌特异性死亡率(HR 1.11,P=0.436)及转移(HR 1.06,P=0.647)无显著关联。
  • BMI每升高1 kg/m2与全因死亡率降低相关(HR 0.98,P=0.012),但与PCSM和转移无关。

核心结论

  • 在非转移性去势抵抗性前列腺癌患者中,肥胖与更好的总生存相关,但与前癌特异性结局无关。

研究设计与样本

  • BMI按低体重(<21 kg/m2)、正常(21-24.9 kg/m2)、超重(25-29.9 kg/m2)、肥胖(≥30 kg/m2)分组。
  • 采用竞争风险回归和Cox模型分析BMI与转移、前列腺癌特异性死亡和全因死亡的关系。

主要发现

  • 人群中低体重51例(4%)、正常体重239例(25%)、超重464例(39%)、肥胖438例(37%)。
  • 调整后,BMI每升高1 kg/m2与全因死亡率降低显著相关(HR 0.98,P=0.012)。
  • BMI每升高1 kg/m2与前列腺癌特异性死亡率(HR 1.00,P=0.737)和转移(HR 0.99,P=0.225)无显著关联。
  • 以正常体重为参照,肥胖与全因死亡率降低显著相关(HR 0.79,P=0.016)。
  • 以正常体重为参照,肥胖与前列腺癌特异性死亡率(HR 1.11,P=0.436)和转移(HR 1.06,P=0.647)无显著关联。

临床怎么用

  • 对于非转移性去势抵抗性前列腺癌患者,肥胖可能提示更好的总生存,但不应据此改变治疗决策。
  • 肥胖与前列腺癌特异性结局无关,仍需关注肥胖相关共病管理。

局限性

  • 缺乏CRPC诊断后所接受治疗的数据。
  • 需要更大规模研究确认上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether obesity is associated with progression to metastasis, prostate cancer-specific mortality (PCSM), and all-cause mortality (ACM), in patients with non-metastatic castration-resistant prostate cancer (non-mCRPC). At the population level, obesity is associated with prostate cancer mortality; however, some studies have found that higher body mass index (BMI) is associated with better long-term prostate cancer outcomes amongst men with mCRPC. PATIENTS AND METHODS: We identified 1 192 patients with non-mCRPC from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BMI was calculated from height and weight abstracted from the medical records at the time closest to but prior to CRPC diagnosis and categorised as underweight (<21 kg/m2 ), normal weight (21-24.9 kg/m2 ), overweight (25-29.9 kg/m2 ), and obese (≥30 kg/m2 ). Competing risks regression and Cox models were used to test associations between obesity and progression to metastasis, PCSM, and ACM, accounting for confounders. RESULTS: Overall, 51 (4%) men were underweight, 239 (25%) were normal weight, 464 (39%) were overweight, and 438 (37%) were obese. In adjusted analysis, higher BMI was significantly associated with reduced ACM (hazard ratio [HR] 0.98, P = 0.012) but not PCSM (HR 1.00, P = 0.737) or metastases (HR 0.99, P = 0.225). Likewise, when BMI was treated as a categorical variable in adjusted models, obesity was not associated with PCSM (HR 1.11, P = 0.436) or metastases (HR 1.06, P = 0.647), but was associated with decreased ACM (HR 0.79, P = 0.016) compared to normal weight. No data were available on treatments received after CRPC diagnosis. CONCLUSIONS: Amongst patients with non-mCRPC obesity was associated with better overall survival. Although this result mirrors evidence from men with mCRPC, obesity was not associated with prostate cancer outcomes. Larger studies are needed to confirm these findings.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vidal AC, Howard LE, de Hoedt A, et al. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018. PMID: 29521009. doi:10.1111/bju.14193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。